Discover and read the best of Twitter Threads about #ESMO2019
Most recents (4)
Surprise surprise. The group that benefits from 1L pembro is largely driven by MSI-high tumors. This should have been included in the original #ASCO2019 presentation. 😡 #KN062 #ESMO2019
Surprise surprise. Patients with ctDNA detectable post-op do worse. IDEA France stage III. #ESMO2019 
FIGHT-202 anti-FGFR2 pemigatinib for FGFR2 fusion cholangiocarcinoma. Very impressive
3-arm non-randomized phase 2
Primary endpoint ORR in cohort A FGFR2 fusion cohort
Randomized phase 1b (never heard of such a thing?) atezo vs atezo/bev. Looks good. Let’s see the prospective study already accrued and hopefully reading out soon. #ESMO2019
IMBRAVE150 sorafenib vs atezo/bev
Phase 3 first line study
Phase 3 first line study
Waterfall plot impressive. Let’s see if it holds up in phase 3
